Ergoteles’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ergoteles’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-96,027	Closed	-$6.54M	–	2178
2022 Q3	$6.54M	Buy	96,027 +87,544	+1,032%	+$4.83M	0.23%	88
2022 Q2	$271K	Buy	+8,483	New	+$248K	0.01%	1162
2022 Q1	–	Sell	-9,263	Closed	-$271K	–	1762
2021 Q4	$271K	Buy	+9,263	New	+$287K	0.01%	900
2021 Q2	–	Sell	-91,449	Closed	-$3.73M	–	1755
2021 Q1	$3.73M	Buy	+91,449	New	+$4.2M	0.12%	201
2020 Q4	–	Sell	-52,126	Closed	-$2.87M	–	980
2020 Q3	$2.87M	Buy	+52,126	New	+$3.31M	0.38%	51

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ergoteles's GBT Position: Q4 2022 in Review

Ergoteles sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 96,027 shares — an estimated $6.54M sold.

Ergoteles first reported a position in GBT in Q3 2020 and held it in 5 quarters. The position peaked at $6.54M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Ergoteles reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 96,027 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $6.54M.
Ergoteles first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
Ergoteles's Global Blood Therapeutics, Inc. position peaked at $6.54M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.